Paper39653296
Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer's disease.
Mojarad-Jabali S and 1 other. Int J Pharm, 2025. Cited by 13 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer's disease. Papers, record 39653296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39653296
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer's disease.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alzheimer Disease | Major topic |
| Nanoparticles | Major topic |
| Amyloid beta-Peptides | Major topic |
| Peptides | Major topic |
| tau Proteins | Major topic |
| Blood-Brain Barrier | Major topic |
| Humans | |
| Animals | |
| Drug Delivery Systems | |
| Brain |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42022743 | Mechanistic research on the vestibular-hippocampal pathway in neurodegenerative diseases: an integrative perspective from molecular to behavioral levels. | Front Neurosci | 2026 | https://conductscience.org/library/papers/42022743 | PubMed |
| 42007396 | Peptide-Based Therapeutics for Alzheimer's Disease: Medicinal Chemistry, AI-Guided Computational Design, and Blood-Brain Barrier Delivery. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42007396 | PubMed |
| 42005708 | Deep Tumor Penetration Using Nanoparticle Delivery Systems: Programmed Design Strategies and Emerging Evaluation Platforms. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42005708 | PubMed |
| 41945238 | Peptide-based therapeutics in the management of Alzheimer's disease (AD) and their potential to develop novel strategies. | Metab Brain Dis | 2026 | https://conductscience.org/library/papers/41945238 | PubMed |
| 41772129 | Brain peptides in Alzheimer's disease - pathophysiology and therapeutic advances. | Cell Tissue Res | 2026 | https://conductscience.org/library/papers/41772129 | PubMed |
| 41231278 | Therapeutic Potential of HAEEPGP Peptide Against β-Amyloid Induced Neuropathology. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/41231278 | PubMed |
| 41226208 | Vitamin-Conjugated Metallic Nanoparticles: Applications for Antimicrobial and Anti-Cancer Drug Delivery. | Molecules | 2025 | https://conductscience.org/library/papers/41226208 | PubMed |
| 40817125 | HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40817125 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APP | 351 | PubTator's text mining | https://conductscience.org/library/genes/351 | NCBI Gene |
| MAPT | 4137 | PubTator's text mining | https://conductscience.org/library/genes/4137 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39653296
GET https://conductscience.org/api/papers/v1/39653296/authors